Literature DB >> 3580012

Failure of tetracycline therapy in early Lyme disease.

R J Dattwyler, J J Halperin.   

Abstract

We describe the clinical courses of 5 patients with Lyme disease who developed significant late complications, despite receiving tetracycline early in the course of their illness. All 5 patients had been treated for erythema chronicum migrans with a course of tetracycline that met or exceeded current recommendations. The late manifestations of Lyme disease included arthritis, cranial nerve palsy, peripheral neuropathy, chronic fatigue, and changes in mental function. Our findings suggest that the use of tetracycline at a dosage of 250 mg, 4 times a day for 10 days, as a treatment for early Lyme disease should be reconsidered. To determine optimal therapy for early Lyme disease, a study that compares an increased dosage of tetracycline with alternative treatments is indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580012     DOI: 10.1002/art.1780300414

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

1.  Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins.

Authors:  M E Brandt; B S Riley; J D Radolf; M V Norgard
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

Review 2.  Laboratory aspects of Lyme borreliosis.

Authors:  A G Barbour
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

3.  Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis.

Authors:  V Preac-Mursic; K Weber; H W Pfister; B Wilske; B Gross; A Baumann; J Prokop
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

4.  Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G.

Authors:  W Kohlhepp; P Oschmann; H G Mertens
Journal:  J Neurol       Date:  1989-12       Impact factor: 4.849

5.  Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study.

Authors:  D Hassler; L Zöller; M Haude; H D Hufnagel; F Heinrich; H G Sonntag
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

6.  Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants.

Authors:  V P Mursic; G Wanner; S Reinhardt; B Wilske; U Busch; W Marget
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

7.  Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.

Authors:  F Breier; G Kunz; H Klade; G Stanek; E Aberer
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

8.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 9.  Current recommendations for the treatment of Lyme disease.

Authors:  L H Sigal
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.